Lead Product(s) : Bucillamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : IND Enabling
Sponsor : Attwill Medical Solutions
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims for the clinical and commercial development of Revive’s lyophilized formulation of Bucillamine, a potent antioxidant and anti-inflammatory and may be helpful for orphan indications in rare inflammatory disorders such as ischemia-...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) : Bucillamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : IND Enabling
Sponsor : Attwill Medical Solutions
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Bucillamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ODD validates strategy in pursuing novel uses of Bucillamine, a cysteine derivative reactivating this endogenous defense against oxidant injury for rare disorders and life-threatening conditions, including infectious diseases and preventing IRI.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2022
Lead Product(s) : Bucillamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bucillamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Revive believes the use of Bucillamine during liver transplantation has the potential to be a safe and effective approach to address the unmet medical need for a novel strategy to limit or prevent ischemia–reperfusion injury (IRI) during liver transpla...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 23, 2021
Lead Product(s) : Bucillamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chitosan-PRP
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ortho Regenerative Technologies Receives Clinical Hold Letter from The U.S. FDA
Details : FDA has requested additional CMC related information on Ortho Regenerative's Investigational New Drug application to begin a phase I/II clinical trial for ORTHO-R, its drug/biologic combination product candidate used as an adjunct to SOC surgery in rota...
Product Name : ORTHO-R
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 06, 2021
Lead Product(s) : Chitosan-PRP
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable